Intra-Cellular Therapies (NASDAQ:ITCI) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) in a report released on Saturday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.

• MarketBeat Week in Review – 01/13 - 01/17

Other analysts have also recently issued reports about the stock. Mizuho cut shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and reduced their price objective for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Baird R W lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Royal Bank of Canada reissued a "sector perform" rating and set a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Piper Sandler reaffirmed a "neutral" rating and issued a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, Leerink Partnrs cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Eleven analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, Intra-Cellular Therapies currently has an average rating of "Hold" and a consensus target price of $106.23.

Get Our Latest Research Report on ITCI

Intra-Cellular Therapies Stock Performance

• Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

NASDAQ ITCI opened at $131.87 on Friday. The business's fifty day moving average is $129.62 and its 200 day moving average is $101.43. Intra-Cellular Therapies has a fifty-two week low of $64.09 and a fifty-two week high of $131.98. The company has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, sell-side analysts forecast that Intra-Cellular Therapies will post -0.64 EPS for the current year.

Institutional Investors Weigh In On Intra-Cellular Therapies

• Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals

Several large investors have recently bought and sold shares of the business. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Intra-Cellular Therapies by 124.3% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 133 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Intra-Cellular Therapies by 1.6% in the fourth quarter. Wellington Management Group LLP now owns 1,033,743 shares of the biopharmaceutical company's stock valued at $86,338,000 after acquiring an additional 16,096 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in Intra-Cellular Therapies by 36.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 12,010 shares of the biopharmaceutical company's stock valued at $1,003,000 after purchasing an additional 3,200 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Intra-Cellular Therapies in the 4th quarter worth about $7,951,000. Finally, GF Fund Management CO. LTD. purchased a new stake in Intra-Cellular Therapies in the 4th quarter worth about $186,000. Institutional investors own 92.33% of the company's stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

Read More

• Five stocks we like better than Intra-Cellular Therapies
• Investing in Travel Stocks Benefits
• Archer Aviation’s Africa Deal Could Boost ACHR Stock
• Top Biotech Stocks: Exploring Innovation Opportunities
• Are Short Sellers Wrong About These 3 Semiconductor Stocks?
• EV Stocks and How to Profit from Them
• Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Intra-Cellular Therapies Right Now?

Before you consider Intra-Cellular Therapies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.

While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here